A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Lead
Hoffmann-La Roche
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
PMS, in accordance with the revised 2017 McDonald criteria
Expanded disability status scale (EDSS) at screening between 3.0 and 6.0 inclusive
Documented evidence of disability progression independent of relapse activity over the 2 years before the screening visit
You may not be if
MS relapse during the 6 months preceding the randomization date
Lack of peripheral venous access
History of alcohol or other drug abuse (substance use disorder) based on Diagnostic and Statistical Manual for Mental Disorders, fifth edition (DSM-5) criteria, within 5 years prior to screening
Inability to complete a magnetic resonance imaging (MRI)
Contraindications to ocrelizumab mandatory pre-medications
Treatment with intravenous immunoglobulin (IV Ig) or plasmapheresis within 12 weeks prior to screening
Clareo Health | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
